Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMY757D)

Drug Name	Pelacarsen DMY757D
Drug Type	Antisense oligonucleotide

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hyperlipoproteinemia	DISVBLBO	5C80	Phase 3	[1]
Cardiovascular disease	DIS2IQDX	BA00-BE2Z	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05900141) A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04023552) A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease. U.S.National Institutes of Health.